Log on / register
BioMed Central home | Journals A-Z | Feedback | Support | My details

Comments(1)

A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"

Lisa H Butterfield email, Mary L Disis email, Bernard A Fox email, Peter P Lee email, Samir N Khleif email, Magdalena Thurin email, Giorgio Trinchieri email, Ena Wang email, Jon Wigginton email, Damien Chaussabel email, George Coukos email, Madhav Dhodapkar email, Leif Håkansson email, Sylvia Janetzki email, Thomas O Kleen email, John M Kirkwood email, Cristina Maccalli email, Holden Maecker email, Michele Maio email, Anatoli Malyguine email, Giuseppe Masucci email, A Karolina Palucka email, Douglas M Potter email, Antoni Ribas email, Licia Rivoltini email, Dolores Schendel email, Barbara Seliger email, Senthamil Selvan email, Craig L Slingluff Jr email, David F Stroncek email, Howard Streicher email, Xifeng Wu email, Benjamin Zeskind email, Yingdong Zhao email, Mai-Britt Zocca email, Heinz Zwierzina email and Francesco M Marincola email

Journal of Translational Medicine 2008, 6:81doi:10.1186/1479-5876-6-81

Additional information on the collaborative groups involved in the Taskforce

Lisa Butterfield   (25 February 2009)  University of Pittsburgh email

The iSBTc has brought together experts from multiple stakeholders who have been focusing significant effort in this area including the United States Food and Drug Administration (FDA); the National Cancer Institute (NCI); the National Institutes of Health (NIH); members from industry; and partnering organizations such as the Biotherapy Development Association (BDA), Association for Immunotherapy of Cancer (CIMT), Cancer Vaccine Consortium (CVC), Nordic Center for Development of Antitumour Vaccines (NCV-network), the Italian Network for Tumor Biotherapy (NIBIT) as well as academic experts in the field of immunologic biomarker development and standardization. The planned October 2009 workshop is unique in that it is meant to be an interactive exchange rather than merely a didactic exercise, as it is organized around lively discussion and sharing of data on biomarker development. Ultimately, the workshop will define the “state of the art” in assay and cellular product development and standardization.

"iSBTc-FDA-NCI Workshop on Prognostic and Predictive Immunologic Biomarkers in Cancer", to take place October 28, 2009, Washington, D.C.
Website: www.isbtc.org

Competing interests

no competing interests, other than paper co-author and workshop co-organizer.

top

Have something to say? Post a comment on this article!


© 1999-2010 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.